Opinion|Videos|June 14, 2024
Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression
Heidi Crayton, MD, and Maria Lopes, MD, discuss the impact of multiple sclerosis on patients, families, and caregivers, differentiate relapsing forms (relapsing-remitting and primary progressive) from non-relapsing forms (non-relapsing secondary progressive) in clinical practice, and highlight the key pathophysiological features of relapsing multiple sclerosis and the impact of progression independent of relapse activity (PIRA) after an initial demyelinating event.
Advertisement
Episodes in this series
- Patients with MS typically experience significant clinical impact. How does the disease impact patients, as well as their families and other caregivers?
- How are relapsing forms of MS (eg, RELAPSING MULTIPLE SCLEROSIS, PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS) differentiated in clinical practice from non-relapsing forms (non-relapsing secondary progressive multiple sclerosis)?
- What are the key features of the pathophysiology of RELAPSING MULTIPLE SCLEROSIS and the impact of progression independent of relapse activity (PIRA) after a first demyelinating
event ? - What are the hallmark features of non-relapsing secondary progressive multiple sclerosis and what is the prevalence of non-relapsing secondary progressive multiple sclerosis seen in clinical practice?
Advertisement
Related to this article
A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
The analysis found a nonlinear association between systemic inflammation and overactive bladder, with stronger links at higher inflammation levels.
A real-world study found that adding a GLP-1 to SGLT2 inhibitor therapy was associated with lower kidney, cardiovascular, and mortality risks in CKD.
In experiments at MD Anderson, rising CD70 helps mantle cell lymphoma evade immunity; a CD70×CD3 bispecific restores T-cell killing and prolongs survival in resistant models.
Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
2
IRA, 340B, Medicaid: The Policy Pressures on Community Oncology
3
Vibegron Outranks Mirabegron, Tolterodine on Several OAB Measures
4
Drug Price Drives Value of MASH Therapies More Than Efficacy
5